Anavex Life Sciences Corp (AVXL)

[Anshu2]

You need to understand what an “intermediate endpoint” means. It is ANY clinical endpoint — that is “reasonably likely to predict final/established clinical endpoint” as per FDA.

Is OR “reasonably likely to predict improvement in delta-Cog or delta-ADL”?

I’d say yes, if n is high. Of course. Thus. FDA may easily consider OR as an intermediate-endpoint. But approval may depend upon n and other factors (dose arms, etc) — which imo makes it unlikely.